Infant ALK-Positive Anaplastic Large Cell Lymphoma with Unfavourable Prognostic Features and Neutrophilia at PresentationAndrea M Malone1*, Lorna Storey1, Michael McDermot2 and Owen P Smith1
- *Corresponding Author:
- Andrea M Malone
Departments of Haematology
Our Lady’s Children’s Hospital
Dublin 12, Ireland
Tel: +353 1 409 6100
E-mail: [email protected]
Received April 13, 2016; Accepted April 25, 2016; Published April 27, 2016
Citation: Malone AM, Storey L, McDermot M, Smith OP (2016) Infant ALK-Positive Anaplastic Large Cell Lymphoma with Unfavourable Prognostic Features and Neutrophilia at Presentation. J Clin Case Rep 6:778. doi:10.4172/2165-7920.1000778
Copyright: © 2016 Malone AM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Anaplastic large cell lymphoma (ALCL) is an uncommon form of non-Hodgkin lymphoma in younger patients, accounting for less than 15% of cases. It is exceedingly rare in infants, with a median age at diagnosis of 12 years. Various treatment strategies have been studied in pediatric ALCL, however the long-term event free survival is approximately 70% regardless of treatment approach. We present the case of six month old infant with anaplastic lymphoma kinase (ALK) positive ALCL with unfavourable prognostic features. We elected to treat with upfront brentuximab in addition to combination chemotherapy. This achieved a clinical and molelcular remission of the disease. The treament was well tolerated.